Among the early breast cancer patients, the marker expression was compared to clinical parameters such as patient age, HER2 status, estrogen (ER) and progesterone receptor (PR) status, lymphangioinvasion, KI 67 label index, and tumor grade. Here, ERBB2 is linked to neoplasm.